ClinicalTrials.gg
RecruitingNCT07400783Updated Nov 18, 2026

TED_ORG: Study on Short Bowel Syndrome

An interventional study of Teduglutide (ALX-0600) and No Treatment Added in Short Bowel Syndrome (SBS), sponsored by Meyer Children's Hospital IRCCS. Recruiting at 1 site in Italy. Open to participants aged 4 Months to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Meyer Children's Hospital IRCCS · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Oct 2024, registered Jan 2026).
  • Started Oct 2024; still recruiting 2 years later.
Updated Nov 18, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
4 Months to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 20 studies testing teduglutide in Short Bowel Syndrome — 1 open to participants now, 2 under way, 1 of them phase 3. teduglutide · Short Bowel Syndrome.

Planned enrollment
7th of 20
50 · median 20
Started
2024
the only one that year
No phase
Only one
of the 20
Registered
20th of 20
by date
Lead sponsor
1 of 20
Meyer Children's Hospital IRCCS

Among the 20 studies testing teduglutide in Short Bowel Syndrome, this one is the 7th largest by planned enrollment, is the only one that started in 2024, is the only one with no phase, and was the 20th registered.

Short Bowel Syndrome

159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.

Browse Short Bowel Syndrome studies →

Open to participants now

1 of the 20 studies testing teduglutide in Short Bowel Syndrome is open now, in 1 country.

By country, each count listing its studies:

About teduglutide

teduglutide: first FDA approval 2012 (GATTEX KIT), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 4 Months to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing teduglutide in Short Bowel Syndrome, or all of them as a file.
02

Study summary

The goal of this clinical trial is to understand why pediatric patients with short bowel syndrome respond differently to treatment with the glucagon-like peptide-2 (GLP-2) analogue teduglutide. Short bowel syndrome is a rare and severe condition in children that results from extensive intestinal resection and leads to impaired nutrient absorption, chronic diarrhea, and dependence on parenteral nutrition. Although teduglutide is known to promote intestinal adaptation and improve absorption, the clinical response varies widely among patients, and the biological mechanisms underlying this variability are not fully understood.

This study aims to investigate the effects of teduglutide using human intestinal organoids derived from intestinal tissue samples of pediatric patients with short bowel syndrome. Intestinal organoids are three-dimensional structures grown from patient-derived stem cells that reproduce key structural and functional characteristics of the human intestine. These organoids provide a human-based experimental model that allows the study of intestinal morphology, cellular behavior, and nutrient absorption in a controlled in vitro environment.

The main questions this study aims to answer are:

Does treatment with teduglutide improve the absorptive capacity of human intestinal organoids derived from pediatric patients with short bowel syndrome?

Are there differences in intestinal structure, cellular proliferation, and gene expression between teduglutide-treated organoids and untreated organoids?

Are specific molecular or cellular features associated with different responses to teduglutide?

Researchers will compare intestinal organoids treated with teduglutide to untreated organoids obtained from the same patients. This comparison will be used to evaluate changes in organoid morphology, expression of receptors involved in intestinal growth and absorption, activity of nutrient transporters, and overall absorptive function. The study will also explore differences between organoids derived from patients who show different clinical responses to teduglutide.

Participants in this study are pediatric patients with short bowel syndrome or patients undergoing intestinal resection surgery as part of their standard clinical care. No experimental treatment is administered directly to participants as part of this study. Intestinal tissue samples are collected only during clinically indicated surgical procedures and are not obtained specifically for research purposes.

Participants will:

Provide intestinal tissue samples collected during routine or clinically indicated intestinal surgery

Have intestinal organoids generated from their tissue samples using established laboratory techniques

Have their organoids studied in vitro with and without exposure to teduglutide to evaluate intestinal structure, gene and protein expression, and nutrient absorption mechanisms

The results of this study are expected to improve understanding of the biological mechanisms underlying variable responses to teduglutide and may contribute to the development of more personalized treatment strategies for pediatric patients with short bowel syndrome in the future.

03

Conditions studied

  • Short Bowel Syndrome (SBS)

Browse trials for

04

Who can participate

Ages eligible
4 Months to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients or His/her Parents/ legal guardian must provide before they can participate in the study.
  • Paediatric patients: Male and female patients aged ≥ 4 months old and ≤ 18 years;
  • SBS patient or patient undergoing intestinal resective surgery

Exclusion criteria

Exclusion Criteria:

  • Adult patients (≥ 18 years old);
  • Patients who have never undergone intestinal resective surgery
  • Current or past use of teduglutide
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Other
    teduglutide-treated organoids

    Human intestinal organoids derived from pediatric patients with short bowel syndrome are treated in vitro with teduglutide to assess its effects on intestinal morphology, gene and protein expression, and nutrient absorption.

    Drug: Teduglutide (ALX-0600)

  • Other
    Untreated organoids

    Human intestinal organoids derived from pediatric patients with short bowel syndrome are maintained in vitro without exposure to teduglutide and serve as a control group for comparison.

    Other: No Treatment Added

Interventions

  • DrugTeduglutideStudies of TeduglutideTeduglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Teduglutide is a glucagon-like peptide-2 (GLP-2) analogue. In this study, teduglutide is used in vitro on human intestinal organoids derived from pediatric patients with short bowel syndrome. The intervention is applied only to organoid cultures and is not administered directly to study participants. Teduglutide-treated organoids are compared with untreated control organoids to evaluate differences in intestinal structure, gene and protein expression, and nutrient absorption.

  • OtherNo Treatment Added

    No Treatment Added

06

What researchers measure

Primary outcomes

  1. Intestinal organoid diameter after in vitro exposure to teduglutide

    Quantitative measurement of intestinal organoid diameter assessed by image-based analysis in patient-derived human intestinal organoids treated in vitro with teduglutide and compared with untreated organoids from the same participant.

    Time frame: During in vitro treatment period (up to 7 days)

  2. Crypt-villus-like architecture in intestinal organoids

    Quantitative assessment of crypt-villus-like architectural features in patient-derived human intestinal organoids following in vitro exposure to teduglutide, evaluated by image-based morphological analysis and compared with untreated organoids from the same participant.

    Time frame: During in vitro treatment period (up to 7 days)

  3. Organoid shape (sphericity) after in vitro teduglutide treatment

    Quantitative measurement of organoid shape, expressed as sphericity index, in patient-derived human intestinal organoids treated in vitro with teduglutide and compared with untreated organoids from the same participant.

    Time frame: During in vitro treatment period (up to 7 days)

  4. Lumen size in intestinal organoids after in vitro exposure to teduglutide

    Quantitative measurement of lumen size assessed by image-based analysis in patient-derived human intestinal organoids treated in vitro with teduglutide and compared with untreated organoids from the same participant.

    Time frame: During in vitro treatment period (up to 7 days)

  5. Intestinal organoid volume after in vitro exposure to teduglutide

    Quantitative measurement of intestinal organoid volume assessed by image-based analysis in patient-derived human intestinal organoids treated in vitro with teduglutide and compared with untreated organoids from the same participant.

    Time frame: During in vitro treatment period (up to 7 days)

  6. Lumen integrity in intestinal organoids after in vitro exposure to teduglutide

    Quantitative assessment of lumen integrity assessed by image-based analysis in patient-derived human intestinal organoids treated in vitro with teduglutide and compared with untreated organoids from the same participant.

    Time frame: During in vitro treatment period (up to 7 days)

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Jan 2027, 27 months after the start.

Of 24 interventional studies with no phase under Short Bowel Syndrome, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 59. This study's planned 27 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Mar 2026 → Jan 2027 and completion Oct 2026 → Feb 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2026
First posted
Feb 10, 2026
StartActual
Oct 30, 2024
Primary completionEst.
Jan 2027was Mar 2026
CompletionEst.
Feb 2027was Oct 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Mar 2026→Jan 2027
Nov 18, 2026
Study completion
Oct 2026→Feb 2027
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Primary completion Mar 2026→Jan 2027
    Study completion Oct 2026→Feb 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07400783
Lead sponsor
Meyer Children's Hospital IRCCS
Responsible party
Antonino Morabito (Surgery and Pediatric Autologous Bowel Reconstruction Rehabilitation & Regenerative Medicine, Meyer Children's Hospital IRCCS) — Principal investigator
First posted
Feb 10, 2026
Start date
Oct 30, 2024
Primary completion
Jan 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Nov 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teduglutide

Start the discussion